The FDA on Tuesday approved etuvetidigene autotemcel (Waskyra) as the first cell-based gene therapy for patients 6 months and ...

The U.S. Food and Drug Administration has approved Waskyra (etuvetidigene autotemcel), the first cell-based gene therapy for ...

Second FDA designation for SENTI-202 this year, after Orphan Drug Designation, is supported by clinical data showing deep and durable complete remission rates combined with a well-tolerated safety ...

ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high efficacy: 50% ORR and 42% CR/CRh (100% of CRs and 83% of ...

Representing a variety of public and private sectors, guests from technology and finance to education and the ...

The global bioconjugation market is projected to grow at an estimated CAGR of close to 13% over the next five years. This growth is fueled by the rising need for targeted therapies, continuous ...

GHR Infra, Lakshmi Infra, and Urbanblocks Realty developers further strengthened their realty leadership in Hyderabad by ...

Poolbeg Pharma plc - POLB 001 trial to feature in groundbreaking cancer immunotherapy-induced CRS research programme RISE ...

Atypical Parkinsonism, a collection of neurodegenerative diseases that share symptoms with Parkinson's Disease but have unique features, poses challenges for patients and healthcare providers. They ...

In 2023, Japan's market size for Paroxysmal Nocturnal Hemoglobinuria therapeutics was around USD 88.5 million, with expectations of growth throughout the forecast period (2024-2034). Projections ...